Searchable abstracts of presentations at key conferences in endocrinology

ea0029s28.3 | Osteoporosis treatment in 2012 and beyond | ICEECE2012

Other emerging therapies

Ebeling P.

Current osteoporosis therapy is predominantly ‘anti-resorptive’. Oestrogen antagonises the action of RANK-Ligand, a potent cytokine for osteoclast differentiation. Amino-bisphosphonates inhibit the HMG CoA reductase pathway, reducing osteoclast activity and viability, while denosumab is a human monoclonal antibody that binds to RANKL. Denosumab treatment reduces fractures. In a study of 7868 women with postmenopausal osteoporosis, denosumab reduced new radiographic v...

ea0036P19 | (1) | BSPED2014

Young adults with Klinefelter syndrome and congenital anorchia treated with testosterone from adolescence have normal bone and muscle mass but increased central adiposity

Wong S C , Scott D , Smriti T , Ebeling P , Zacharin M

Background: Decreased bone mineral density using dual energy absorptiometry (DXA) is reported in mixed cohorts of testosterone treated and testosterone naïve men with Klinefelter syndrome (KS). Bone mass and body composition in men with congenital anorchia (CA) have not been reported.Hypothesis: Men with KS and CA treated with testosterone from adolescence have normal bone mass and body composition.Methods: DXA and pQCT were p...